Roosevelt Investment Group LLC raised its holdings in Pfizer Inc. (NYSE:PFE) by 1.7% in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 92,642 shares of the biopharmaceutical company’s stock after purchasing an additional 1,518 shares during the quarter. Roosevelt Investment Group LLC’s holdings in Pfizer were worth $3,628,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Other large investors have also made changes to their positions in the company. Benjamin Edwards Inc. grew its stake in Pfizer by 36.5% in the 1st quarter. Benjamin Edwards Inc. now owns 999 shares of the biopharmaceutical company’s stock valued at $36,000 after purchasing an additional 267 shares during the period. Alpha DNA Investment Management LLC grew its stake in shares of Pfizer by 52.2% during the 1st quarter. Alpha DNA Investment Management LLC now owns 1,090 shares of the biopharmaceutical company’s stock worth $39,000 after acquiring an additional 374 shares during the period. Lake Point Wealth Management bought a new position in shares of Pfizer during the 2nd quarter worth $49,000. Harvest Fund Management Co. Ltd grew its stake in shares of Pfizer by 25,460.0% during the 2nd quarter. Harvest Fund Management Co. Ltd now owns 1,278 shares of the biopharmaceutical company’s stock worth $50,000 after acquiring an additional 1,273 shares during the period. Finally, KB Financial Partners LLC bought a new position in shares of Pfizer during the 1st quarter worth $62,000. Hedge funds and other institutional investors own 64.93% of the company’s stock.
Shares of NYSE:PFE traded down $0.02 on Tuesday, hitting $44.18. The company’s stock had a trading volume of 277,325 shares, compared to its average volume of 30,980,998. The company has a 50-day simple moving average of $45.13 and a 200 day simple moving average of $40.64. Pfizer Inc. has a 1 year low of $33.36 and a 1 year high of $51.86. The company has a market capitalization of $247.70 billion, a PE ratio of 19.02, a PEG ratio of 1.58 and a beta of 0.74. The company has a debt-to-equity ratio of 0.50, a current ratio of 1.37 and a quick ratio of 1.12.
The company also recently disclosed a quarterly dividend, which was paid on Tuesday, September 7th. Investors of record on Friday, July 30th were issued a dividend of $0.39 per share. The ex-dividend date of this dividend was Thursday, July 29th. This represents a $1.56 dividend on an annualized basis and a dividend yield of 3.53%. Pfizer’s dividend payout ratio is 70.27%.
In related news, SVP Jennifer B. Damico sold 1,661 shares of the firm’s stock in a transaction dated Friday, August 13th. The stock was sold at an average price of $48.30, for a total transaction of $80,226.30. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, SVP Jennifer B. Damico sold 2,500 shares of the firm’s stock in a transaction dated Friday, July 30th. The shares were sold at an average price of $42.86, for a total value of $107,150.00. Following the transaction, the senior vice president now directly owns 11,430 shares in the company, valued at $489,889.80. The disclosure for this sale can be found here. Company insiders own 0.05% of the company’s stock.
Several research firms have recently weighed in on PFE. The Goldman Sachs Group set a $48.00 price target on Pfizer in a research note on Thursday, July 29th. Royal Bank of Canada set a $44.00 price target on Pfizer in a research note on Thursday, July 29th. SVB Leerink increased their price target on Pfizer from $49.00 to $50.00 and gave the stock a “market perform” rating in a research note on Monday. JPMorgan Chase & Co. increased their price objective on Pfizer from $40.00 to $42.00 and gave the stock a “neutral” rating in a report on Monday, September 13th. Finally, Morgan Stanley increased their price objective on Pfizer from $42.00 to $45.00 and gave the stock an “equal weight” rating in a report on Thursday, July 29th. Eleven analysts have rated the stock with a hold rating and two have given a buy rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Hold” and a consensus target price of $42.85.
Pfizer Inc is a research-based global biopharmaceutical company. It engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases.
Read More: Liquidity
Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE).
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.